6 News & Press Releases found

Kephera Diagnostics, LLC news

Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test.

Kephera Diagnostics has launched a new study aimed at collecting blood samples from volunteers at least 18 years of age who have been confirmed positive for COVID-19,

Apr. 4, 2020

Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer

Kephera Diagnostics has been awarded a $1,999,961 million Phase II Small Business Innovative Research (SBIR) contract by the National Cancer Institute, an agency of the National Institutes of Health, for a test for liver fluke infection, the Company announced today. Kephera had previously received a $300,000 Phase I contract to develop and demonstrate the feasibility of its test.

Liver flukes are acquired by eating raw freshwater fish that are infected with the parasites. They a

Oct. 2, 2021

NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease

The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in response to a targeted solicitation from NIAID aimed at improving diagnostic resources for Chagas disease, will support the development and preliminary evaluation of a

Sep. 3, 2021

Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination

Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through Kephera’s CLIA-certified laboratory.

Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is the key antigen in current COVID-19 vaccines. The test will enable individuals to assess the

Jul. 1, 2021

Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test

Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), to complete the development and launch of a new test for Zika virus infection.

Kephera’s test is aimed at detecting Zika antibodies in a highly specific way that avoids cross-reactivity with the Dengue virus, a serious

Jul. 3, 2020